The U.S. Department of Health and Human Services has announced that Emergent BioSolutions Inc. will be one of three new centers to develop vaccines against bioterrorism threats and pandemic illnesses.
According to excerpts from the article:
Emergent, a Rockville, Md.-based biopharmaceutical company, will partner with Michigan State University, Kettering University in Flint and the University of Maryland to create the Center for Innovation in Advanced Development and Manufacturing. Emergent’s contract spans eight years and is worth $220 million, an amount that will include investments from both the company and the federal government.
Read the entire story
here.